NCT06435923View on ClinicalTrials.gov

A Trial to Assess the Absorption, Metabolism, Excretion, and Mass Balance of [14C]-Darigabat After a Single Oral Dose in Healthy Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

May 29, 2024

Primary Completion Date

July 2, 2024

Study Completion Date

July 3, 2024

Conditions
Healthy Participants
Interventions
DRUG

[14C]-darigabat

Oral capsule

Trial Locations (1)

78744

Austin, Texas, Austin

Sponsors
All Listed Sponsors
lead

Cerevel Therapeutics, LLC

INDUSTRY

NCT06435923 - A Trial to Assess the Absorption, Metabolism, Excretion, and Mass Balance of [14C]-Darigabat After a Single Oral Dose in Healthy Male Participants | Biotech Hunter | Biotech Hunter